Background macular Shape Background macular Shape Background macular Shape
Grants > Therapeutic Evaluation of Alpha Lipoic Acid for Geographic Atrophy Updated On: Jan. 20, 2025
Macular Degeneration Research Grant

Therapeutic Evaluation of Alpha Lipoic Acid for Geographic Atrophy

Geographic Atrophy
Benjamin Kim, MD

Principal Investigator

Benjamin Kim, MD

University of Pennsylvania

Philadelphia, PA, USA

About the Research Project

Program

Macular Degeneration Research

Award Type

Bold Ideas initiatives

Award Amount

$130,000

Active Dates

January 01, 2016 - June 30, 2019

Grant ID

CM2016971

Co-Principal Investigator(s)

Joshua Dunaief, MD, PhD, University of Pennsylvania

Maureen Maguire, PhD, University of Pennsylvania

Goals

The blinding lesions of the geographic atrophy (GA) form of advanced age-related macular degeneration (AMD) are responsible for 20 percent of legal blindness in North America. Research has shown that oxidative stress and iron overload at the retina are major contributors to these atrophic lesions in AMD, consisting of localized areas of dead cells.

Currently, there is no treatment available; however, there is interest in a potent antioxidant and iron chelator called alpha lipoic acid. A chelating agent is a substance whose molecules can form several bonds to a single metal ion, thus suppressing its chemical activity. Alpha lipoic acid is found in many food sources, including spinach, broccoli, and potatoes; it also is manufactured for use as a supplement. Through a Phase II pilot clinical trial, we are testing alpha lipoic acid as a treatment for GA.